A breakthrough
in Non-Opioid
pain medication Learn More

Non-Opioid
Pain Management

WEX is developing a new class of non-opioid analgesics. WEX’s lead product, Halneuron®, is a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain, cancer pain, and other pain indications.

Halneuron® represents a breakthrough in painkiller technology:

  • No evidence of addiction, withdrawal symptoms, or euphoria
  • No build of up of tolerance overtime
  • Clinical evidence demonstrating long duration of pain relief with minimal, mild, and temporary side effects
  • Tested in over 700 people in over 15 clinical trials

The Technology

Halneuron® is Tetrodoxin (TTX), a highly selective sodium blocker that binds to the NAv 1.7 to block the transmission of pain signals and relieve pain. Unlike opioids, TTX is not addictive to the user and does not cause typical opioid-like side effects.

Read More

Clinical Trials

WEX has successfully conducted 15 clinical trials with TTX. Over 700 people have been treated with TTX to date. Halneuron® is actively being tested in human clinical trials, and is in the process of preparing for a double-blinded, placebo-controlled Phase 3 trial.

Read More

We need a headline here

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore fugiat sunt culpa officia deserunt mollit anim est laborum.

For Physicians

For Investors

For Media

Quick Links
Contact Us

Copyright 2022. All Rights Reserved.